Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Focal Cryo-Ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.

Urology·2026
Same author

Indigo Carmine Visualization Duration in Urine: A Randomized Kinetics Study.

Urogynecology (Philadelphia, Pa.)·2026
Same author

How urology can embrace the patient-centric precision focal therapy approach for localized prostate cancer.

Nature reviews. Urology·2026
Same author

Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity.

Advances in radiation oncology·2026
Same author

Qualitative assessment of facilitators and barriers to testicular torsion care: Findings from the testicular torsion collaborative.

Journal of pediatric urology·2026
Same author

Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.

European radiology·2026
Same journal

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same journal

We Care, and We Will Listen.

Primary care·2026
Same journal

Addressing Sexual Health in Primary Care.

Primary care·2026
Same journal

Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.

Primary care·2026
Same journal

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same journal

Nonpharmacologic Management of Insomnia Disorder in Primary Care.

Primary care·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Prostate-specific antigen testing and prostate cancer screening.

Bob Djavan1, Elisabeth Eckersberger, Julia Finkelstein

  • 1Department of Urology, New York University School of Medicine (NYU), New York University Hospital, 150 East 32nd Street, New York, NY 10016, USA. bdjavan@hotmail.com

Primary Care
|August 14, 2010
PubMed
Summary
This summary is machine-generated.

Prostate specific antigen (PSA) screening is a key tool for prostate cancer detection. However, recent studies question its impact on mortality and patient quality of life, necessitating further research.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jun 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

  • Urology
  • Oncology
  • Medical Screening

Background:

  • Prostate specific antigen (PSA) screening, often with digital rectal exams, is a standard prostate cancer detection method recommended by the American Cancer Society.
  • PSA screening has led to earlier cancer detection (stage migration) over recent decades.
  • Various forms of PSA (free, complexed, intact, pro-PSA) are utilized in screening.

Purpose of the Study:

  • To review the current role and impact of prostate specific antigen (PSA) screening in prostate cancer detection.
  • To examine the evolving landscape of PSA screening, including different PSA forms and related factors like age at diagnosis and survival.
  • To address concerns regarding overdiagnosis, overtreatment, and the effect of PSA screening on patient quality of life.

Main Methods:

  • Review of recent studies and literature concerning PSA screening for prostate cancer.
  • Analysis of the implications of PSA screening on stage migration, diagnostic methods, and patient outcomes.
  • Consideration of factors such as age, survival rates, overdiagnosis, and overtreatment in the context of PSA screening.

Main Results:

  • PSA screening has significantly altered the stage at which prostate cancer is diagnosed.
  • Emerging research raises questions about the definitive positive impact of PSA screening on mortality rates.
  • The quality of life implications for patients undergoing PSA screening require further investigation.

Conclusions:

  • The effectiveness of PSA screening in reducing prostate cancer mortality remains a subject of ongoing debate.
  • Further longitudinal studies are essential to fully understand the long-term benefits and harms of PSA screening.
  • Future research should explore the potential of different PSA components for more precise prostate cancer detection and management.